IL5 and Increased total eosinophil count: Indication for an IL‐5 blockade was a therapy-refractory course under CS with persisting or increasing eosinophilia (6/14 [42.9%], cases 1, 4–5, 7–9), severe organ dysfunction (3/14 [21.4%], cases 3, 6, 12), recurrent relapses (3/14 [21.4%], cases 1, 11, 13), continued treatment with the causing drug (1/14 [7.1%], case 14), and concomitant septic shock (1/14 [7.1%], case 2).